La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
64 hedge funds and large institutions have $82.1M invested in La Jolla Pharmaceutical Company in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less capital invested
Capital invested by funds: $86M → $82.1M (-$3.94M)
16% less funds holding
Funds holding: 76 → 64 (-12)
35% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 26
37% less call options, than puts
Call options by funds: $235K | Put options by funds: $375K
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.94M |
| 2 |
D.E. Shaw & Co
New York
|
+$953K |
| 3 |
Morgan Stanley
New York
|
+$941K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$579K |
| 5 |
Goldman Sachs
New York
|
+$390K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.19M |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$985K |
| 3 |
Renaissance Technologies
New York
|
-$806K |
| 4 |
Two Sigma Investments
New York
|
-$374K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$366K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
76
A.R.T. Advisors
New York
| – | -$46K | -10,785 | Closed |
|
77
Walleye Capital
New York
| – | -$43K | -10,194 | Closed |
|
|
FC
78
FORA Capital
Miami,
Florida
| – | -$36K | -8,438 | Closed |
|
|
QI
79
QS Investors
New York
| – | -$3K | -700 | Closed |
|
LJPC Hedge Fund Activity: Q3 2020 in Review
64 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2020, worth a combined $82.1M — down 4.6% from $86M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LJPC and 4 opened new positions — a net loss of 12 holders — while 26 trimmed existing stakes and 17 added.
The largest buyer was Tang Capital Management, adding an estimated $2.94M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.19M sold.
- 64 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2020, down from 76 in Q2 2020.
- Funds reported $82.1M of La Jolla Pharmaceutical Company stock for Q3 2020, down 4.6% quarter-over-quarter.
- 4 funds opened new La Jolla Pharmaceutical Company positions in Q3 2020 and 16 closed out, a net change of -12 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q3 2020 was Tang Capital Management, an estimated $2.94M added.
- The largest La Jolla Pharmaceutical Company seller in Q3 2020 was Acadian Asset Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2020.